Zura Bio Ltd (ZURA) Stock AnalysisZURAZura Bio Ltd

Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Zura Bio Ltd is not a good buy right now due to its current price of $3.36, which is significantly below analyst price targets of $20 and $22. The stock has a very low RSI of 25.949, indicating it is oversold, but the company is facing substantial financial losses with a net income loss of $26.3 million in Q2 2026. The primary risk is the high net loss and declining hedge fund ownership, which decreased from 33 to 24 funds, reflecting skepticism about the company's future prospects.